Pharmacological Treatment of Cannabis Dependence
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Cannabis is the most frequently used illegal psychoactive substance in the world. There is a significant increase in the number of treatment admissions for cannabis use disorders in the past few years, and the majority of cannabis-dependent individuals who enter treatment have difficulty in achieving and maintaining abstinence. Thus, there is increased need for medications that can be used to treat this population. So far, no medication has been shown broadly and consistently effective; none has been approved by any national regulatory authority. Medications studied have included those that alleviate symptoms of cannabis withdrawal (e.g., dysphoric mood, irritability),those that directly affect endogenous cannabinoid receptor function, and those that have shown efficacy in treatment of other drugs of abuse or psychiatric conditions. Buspirone is the only medication to date that has shown efficacy for cannabis dependence in a controlled clinical trial. Results from controlled human laboratory studies and small open-label clinical trials suggest that dronabinol, the COMT inhibitor entacapone, and lithium may warrant further study. Recent pre-clinical studies suggest the potential of fatty acid amide hydrolase (FAAH) inhibitors such as URB597, endocannabinoid-metabolizing enzymes, and nicotinic alpha 7 receptor antagonists such as methyllycaconitine (MLA).Controlled clinical trials are needed to evaluate the clinical efficacy of these medications and to validate the laboratory models being used to study candidate medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070
Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.026 · Cited by 1,409
Comparison of extended versus brief treatments for marijuana use.
Stephens, R. S., Roffman, R. A., & Curtin, L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.5.898 · Cited by 711
Cannabis use disorders in the USA: prevalence, correlates and co-morbidity
STINSON, F. S., RUAN, W. J., PICKERING, R., & GRANT, B. F. (2006) · Psychological Medicine · doi:10.1017/s0033291706008361 · Cited by 422 · cited 1×
“In the United States, the number of individuals with disorders associated with cannabis use is twice that of any other illicit drug [1], with approximately 4 million adults meeting criteria for a life-time diagnosis of cannabis dependence [6].”
BackgroundVolkow, N. D., Wang, G.-J., Fowler, J. S., Hitzemann, R., Angrist, B., Gatley, S. J., Logan, J., Ding, Y.-S., & Pappas, N. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.19 · Cited by 405
A randomized controlled trial of brief cognitive–behavioral interventions for cannabis use disorder
Copeland, J., Swift, W., Roffman, R., & Stephens, R. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00179-9 · Cited by 322 · cited 1×
“Relapse rates for cannabis users in treatment are comparable to those found for other drugs of abuse [7–11].”
ResultDwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259
Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms
Budney, A. J., Vandrey, R. G., Hughes, J. R., Moore, B. A., & Bahrenburg, B. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.014 · Cited by 180
Abstinence rates following behavioral treatments for marijuana dependence
Kadden, R. M., Litt, M. D., Kabela-Cormier, E., & Petry, N. M. (2007) · Addictive Behaviors · doi:10.1016/j.addbeh.2006.08.009 · Cited by 173
Bupropion SR worsens mood during marijuana withdrawal in humans
Haney, M., Ward, A. S., Comer, S. D., Hart, C. L., Foltin, R. W., & Fischman, M. W. (2001) · Psychopharmacology · doi:10.1007/s002130000657 · Cited by 135 · cited 1×
“withdrawal symptoms and had no positive effects [42, 43].”
Background
Cited by
Keep off the grass? Cannabis, cognition and addiction
Curran, H. V., Freeman, T. P., Mokrysz, C., Lewis, D. A., Morgan, C. J. A., & Parsons, L. H. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.28 · Cited by 389
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
Medications for substance use disorders
Douaihy, A. B., Kelly, T. M., & Sullivan, C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.759031 · Cited by 93
Weinstein, A. M., Miller, H., Bluvstein, I., Rapoport, E., Schreiber, S., Bar-Hamburger, R., & Bloch, M. (2014) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.819362 · Cited by 53
Self-citationCOMT val158met and 5-HTTLPR Genetic Polymorphisms Moderate Executive Control in Cannabis Users
Verdejo-García, A., Fagundo, A. B., Cuenca, A., Rodriguez, J., Cuyás, E., Langohr, K., de Sola Llopis, S., Civit, E., Farré, M., Peña-Casanova, J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.59 · Cited by 53
“For example, the COMT inhibitor tolcapone has been proposed as a promising treatment for marijuana dependence (Weinstein and Gorelick, 2011), and its effect should be equivalent to a phenocopying of subjects’ carriers of the val/val genotype to the met/met genotype, resulting in more sustained dopamine brain concentra…”
Background
Metadata
- Authors
- M. Weinstein, A., & A. Gorelick, D.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-05-01
- Volume
- 17
- Issue
- 14
- Pages
- 1351-1358
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2006293549
- Cited by
- 70
- References
- 17
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Treatment of Cannabis Dependence. https://app.cochat.ai/papers/10.2174/138161211796150846
- The paper
- M. Weinstein, A., & A. Gorelick, D. (2011). Pharmacological Treatment of Cannabis Dependence. Current Pharmaceutical Design. https://doi.org/10.2174/138161211796150846
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.